SDHB and paraganglioma: The progression-free survival (PFS) with CVD chemotherapy was 24 months.<h4>Conclusion</h4>This report reviews the distinct clinical and biochemical characteristics and treatment approaches of SDHB-mutated paragangliomas, emphasizing that the significance of incorporating both genetic testing and immunohistochemical analysis in clinical practice.